Compare Krispy Kreme Inc (DNUT) vs Summit Therapeutics Inc (SMMT) Price & Performance

Krispy Kreme (DNUT) trades at $3.14, down 5.99% with bearish technical signals. The company shows mixed fundamentals with a high P/E ratio of 216.5 but attractive P/S of 0.36 and P/B of 0.87. Recent Q2 2026 earnings showed a narrowed loss of $0.03 per share, beating expectations, while revenue declined 12.8% due to refranchising. CEO Josh Charlesworth emphasized turnaround progress with margin improvement and deleveraging (Bloomberg, August 6, 2026).

The outlook remains challenging with negative net income margins and ROE, though analyst sentiment is cautiously optimistic with 50% buy ratings. Key risks include execution of the turnaround strategy and competitive pressures. The stock presents a speculative opportunity if management can sustain operational improvements and return to profitability.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.